Bariatric therapy : alliance between gastroenterologists and surgeons / Elisabeth M. H. Mathus-Vliegen, Jérôme Dargent.
Mathus-Vliegen, Elisabeth M. H., 1949- author.; Dargent, Jérôme, author.
2018
RD540 .M38 2018
Available Online

Linked e-resources

Linked Resource
Online Access
Concurrent users
Unlimited
Authorized users
Authorized users
Document Delivery Supplied
Can lend chapters, not whole ebooks

Details

Title
Bariatric therapy : alliance between gastroenterologists and surgeons / Elisabeth M. H. Mathus-Vliegen, Jérôme Dargent.
Author
Mathus-Vliegen, Elisabeth M. H., 1949- author.
ISBN
9783319900742 (electronic book)
3319900749 (electronic book)
3319900730
9783319900735
DOI
https://doi.org/10.1007/978-3-319-90074-2
Published
Cham, Switzerland : Springer, [2018]
Language
English
Description
1 online resource
Item Number
10.1007/978-3-319-90074-2 doi
Call Number
RD540 .M38 2018
Dewey Decimal Classification
617.4/3
Summary
This book aims to deepen collaboration between gastroenterologists and surgeons by providing endoscopists and gastroenterologists with a clear understanding of the anatomic alterations likely to be observed after bariatric surgery and acquainting bariatric surgeons with the possibilities offered by endoscopic treatment of obesity itself and of the complications associated with bariatric surgery. The treatment approach in patients with obesity and morbid obesity is usually stepwise, starting with dietary measures, exercise, and behavioral therapy, followed by pharmaceutical therapies, endoscopic bariatric therapy, and, finally, bariatric surgery. Endoscopists and gastroenterologists are involved first because the gastrointestinal tract is affected by obesity-related co-morbidity and second because it provides access for a range of treatment modalities involving endoscopy. Bariatric surgeons may need the assistance of endoscopists and gastroenterologists in the preoperative work-up of patients, in the perioperative period, when acute complications may require an endoscopic intervention, or in the late follow-up period, when complications or insufficient weight loss may be present. This book will be of value for both groups of specialists, enabling them to optimize their cooperation to the benefit of patients.
Bibliography, etc. Note
Includes bibliographical references.
Access Note
Access limited to authorized users.
Digital File Characteristics
text file PDF
Source of Description
Description based on online resource; title from digital title page (viewed on December 28, 2018).
Added Author
Dargent, Jérôme, author.
Available in Other Form
Print version: 9783319900735
Linked Resources
Online Access
Record Appears in
Online Resources > Ebooks
All Resources
Intro; Preface; Contents; 1: Epidemiology and Comorbidities; 1.1 Introduction and Epidemiology; 1.2 Definition and Classification; 1.3 Pathogenesis of Comorbidities; 1.3.1 Hormone-Like Adipokines; 1.3.2 Inflammatory Cytokines and Anti-inflammatory Factors; 1.4 Decreased Life Expectancy and Mortality; 1.4.1 Mortality: All-Cause and Disease-Specific Causes; 1.4.2 Population Attributable Fraction; 1.4.3 Current Developments; 1.5 Comorbidities in General; 1.6 Symptoms and Comorbidities More Specifically Related to the Gastrointestinal Tract

1.7 Symptoms Related to the Gastrointestinal Tract1.8 Comorbid Diseases Related to the Gastrointestinal Tract; 1.8.1 Oesophagus and Stomach; 1.8.1.1 Gastro-Oesophageal Reflux Disease; Putative Causative Mechanisms; Mechanical Mechanisms; Humoral Mechanisms; Role of General Adiposity and Visceral Adiposity; Meta-Analyses and Cohort Studies; What Is the Natural History of GORD?; 1.8.1.2 Barrett's Oesophagus; Case-Control Studies and BMI and Waist; Meta-Analyses; The Visceral Fat Pathway; Visceral Fat Measurements; Subcutaneous Fat Measurements; Metabolic Syndrome; Secreted Adipokines

LeptinAdiponectin; Both Leptin and Adiponectin; 1.8.1.3 Oesophageal Adenocarcinoma and Gastro-Oesophageal Junction/Gastric Cardia Adenocarcinoma; Meta-Analyses; Recent Cohort and Case-Control Studies; 1.8.1.4 Gastric Cancer; 1.8.1.5 Implications for Clinical Practice; 1.8.2 Gallbladder and Pancreas; 1.8.2.1 Gallbladder; Gallbladder Stones; Gallstones and Complications; Pathophysiology of Gallstone Formation in Obesity; 1.8.2.2 Pancreas; Acute Pancreatitis; Meta-Analyses; Why Are the Obese at Risk of Acute Pancreatitis and Local and Systemic Complications?; Pancreatic Cancer

1.8.2.3 Implications for Clinical Practice1.8.3 Rectocolon; 1.8.3.1 Colorectal Adenoma; Meta-Analyses; 1.8.3.2 Colorectal Carcinoma; Meta-Analyses; 1.8.3.3 Pathophysiology of Obesity in Relation to Adenoma and Carcinoma; Metabolic Syndrome; Visceral Fat and Adipokines; 1.8.3.4 Implications for Clinical Practice; 1.8.4 Liver; 1.8.4.1 Non-alcoholic Fatty Liver Disease; 1.8.4.2 Hepatocellular Carcinoma; Pathophysiology of Obesity in Relation to NAFLD; Pathophysiology of Obesity in Relation to Hepatocellular Carcinoma; 1.8.4.3 Implications for Clinical Practice

1.8.5 Gastrointestinal Cancers1.8.5.1 Cohort Studies; 1.8.5.2 Meta-Analyses; 1.8.5.3 Implications for Clinical Practice; References; 2: Current Endoscopic/Laparoscopic Bariatric Procedures; 2.1 Introduction; 2.2 Endoscopic Bariatric and Metabolic Therapies; 2.3 Gastric Endoscopic Bariatric and Metabolic Therapies; 2.3.1 Non-invasive Endoscopic Bariatric and Metabolic Therapies; 2.3.1.1 Intragastric Balloon Treatment; Single Ballloons; Orbera Balloon (Formerly Bioenterics Intragastric Balloon (BIB); Apollo Endosurgery, Austin, TX, USA); Efficacy and Safety; Predictors of Weight Loss

Browse Subjects

Show more subjects...

Statistics

from
to
Export